海外の治験の状況「前立腺癌」での検索結果
242件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- PSMA-PET/CT for prostate cancer
- prostate cancer (and metastases);Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- Belgium
- 2017-10-30
Authorised
- Optimisation of [68Ga] PSMA-11 PET/CT Imaging Protocol for finding the location of prostate cancer lesions in patients who were newly diagnosed with prostate cancer
- Primary localised prostate cancer, in men who opt for active treatment in the form of a radical prostatectomy;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12];Primary localised prostate cancer, in men who opt for active treatment in the form of a radical prostatectomy;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12];Primary localised prostate cancer, in men who opt for active treatment in the form of a radical prostatectomy;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- Netherlands
- 2016-10-26
Authorised
- CANTATA: Chemotherapy comparison in relapsing Prostate Cancer that has spread
- Metastatic Castrate Refractory Prostate Cancer;Therapeutic area: Diseases [C] - Cancer [C04]
- United Kingdom
- 2012-11-26
Authorised
- PHASE I/IIa STUDY OF VACCINE THERAPY IN PATIENTS WITH PROSTATE CANCER
- Patients with advanced oligometastatic prostate cancer (PCa) without lung and/or liver metastases who are eligible to Complete Androgen Blockade therapy (GnRH-agonist combined with anti-androgen). MedDRA version: 14.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 14.1 Level: LLT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Norway
- 2012-09-18
Authorised
- Randomized phase III trial comparing Jevtana in combination with hormone therapy to hormone therapy alone in metastatic prostate cancer
- Patients diagnosed with metastatic or high risk(PSA>100 or N1) prostate cancer. br>MedDRA version: 14.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Sweden
- 2011-06-30
Authorised
- 18F-FACBC PET/CT FOR STAGING HIGH RISK PROSTATE CANCER
- Patients affected by moderate to high risk primary prostate cancer who are scheduled for surgery with a planned, elective lymph node dissection MedDRA version: 17.0 Level: LLT Classification code 10036946 Term: Prostatic cancer System Organ Class: 100000004864 ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- Italy
- 2014-08-27
Authorised
- A trial of the combination treatment enzalutamide and AZD5363 for patients with advanced prostate cancer.
- Metastatic Castration- Resistant Prostate Cancer br>MedDRA version: 16.1 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- United Kingdom
- 2014-03-27
Authorised
- Study of the effect of chemotherapy with cabazitaxel on prostate cancer
- Castration resistant bone metastatic prostate cancer br>MedDRA version: 18.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Greece
- 2015-05-12
Authorised
- A study to assess the usefulness of fluciclovine (18F) PET/CT in patients with rising PSA after treatment of prostate cancer
- Prostate cancer with biochemical recurrence after radical treatment MedDRA version: 20.0 Level: PT Classification code 10036911 Term: Prostate cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- United Kingdom
- 2015-04-15
Authorised
- An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Metastatic castration-resistant prostate cancer (mCRPC) MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Belgium, Brazil, Canada, China, France, Germany, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Russian Federation, South Africa, Spain, United Kingdom, United States
- 2014-05-13
